natera™ | Prospera™ Transplant assessment

NEW

The ProReach Program™

Remote care for Prospera™ patients including routine labs, in partnership with a national diagnostics laboratory

Natera's new **ProReach Program** enables you to stay closely connected with your transplant patients. Utilizing our nationwide mobile phlebotomy network, we are now able to draw both Prospera and routine labs remotely, with no additional charge. Additional labs include:

- **BK Virus DNA PCR Quantitative**
- **Complete Blood Count (CBC)**
- **Comprehensive Metabolic Panel**
- **Cyclosporine Levels**
- **Cytomegalovirus DNA PCR Quantitative**
- **Everolimus, Sirolimus and Tacrolimus**
- **Urinalysis**
- **Urine Protein / Creatinine Ratio**

Continuity.
Connection.
Convenience.

Provider set up in two simple steps

Customize how you follow your transplant patients:

1. Place Prospera orders in the **Provider Portal, and indicate mobile draw**
2. Inform your Natera Nurse Coordinator of which patients you'd like to **ADD routine lab work** through a premier diagnostics lab

☐ **Option 1**

Add routine labs on **ALL** Prospera patients

☐ **Option 2**

Include routine labs on **SPECIFIC** Prospera patients

After enrollment, what's next?

Once your patients are enrolled in the ProReach Program, Natera will take care of the rest:

OUTREACH

Collect completed requisition forms from center and mail kits to patient's home

SCHEDULE

Schedule a mobile phlebotomy visit based on the patient's preferred availability

SHIPPING

Coordinate shipping of labs to Natera and diagnostic laboratory

RESULTS

Provide timely Prospera results through your standard delivery channels. Routine lab results provided by partner laboratory

Complete care with Prospera

Prospera enables you to:

- **Catch all rejection types in a single blood draw:** Prospera's unique ability to identify T cell-mediated rejection gives a more holistic view of your patient's rejection status.[1]
- **Minimize risk of missing active rejection:** Prospera is three times less likely to miss an active rejection* than the first-generation donor-derived cell-free DNA test (Negative Predictive Value of 95% vs 84%).[1,2]
- **More accurately classify active rejection:** Prospera demonstrated better performance than the first-generation dd-cfDNA test (sensitivity of: 89% vs 59%) to identify patients with active rejection.[1,2]

JOIN NOW

Enroll all your transplant patients today for peace of mind and timely screening.

Call us +1 650.273.4468
Visit us natera.com/proreach

* 25% prevalence of active rejection

1 Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. *J Clin Med*. 2019;8(1):19.
2 Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. *J Am Soc Nephrol*. 2017;28(7):2221-2232. doi: 10.1681/ASN.2016091034.

201 Industrial Road, Suite 410, San Carlos, CA 94070 | Main +1 650.249.9090 | Fax +1 650.730.2272 | natera.com

natera™